PNGM Competitors

Stocks . USA . 
Stock . Er Therapeutics
PNGM Stock  USD 0.0001  0.00  0.00%   
Er Therapeutics competes with Argentum Silver; as well as few others. The company conducts business under Metals & Mining sector and is part of Materials industry. Analyzing Er Therapeutics competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of Er Therapeutics to its intrinsic valuation because they are able to contrast its competitors on a relative basis. Check out Er Therapeutics Correlation with its peers.
To learn how to invest in PNGM Stock, please use our How to Invest in Er Therapeutics guide.

Er Therapeutics vs Lightspeed Discoveries Correlation

Moving against PNGM Stock

  0.81ATCOL Atlas CorpPairCorr
  0.77NAK Northern Dynasty MineralsPairCorr
  0.75GSM Ferroglobe PLCPairCorr
  0.74SLI Standard LithiumPairCorr
  0.74IE Ivanhoe EnergyPairCorr
At this time, Er Therapeutics' Return On Capital Employed is very stable compared to the past year. As of the 3rd of February 2026, Return On Equity is likely to grow to 1.64, while Return On Tangible Assets are likely to drop (1.41). As of the 3rd of February 2026, Total Assets is likely to drop to about 283.4 K. In addition to that, Net Tangible Assets is likely to grow to about (96.1 K).
Specify up to 10 symbols:
Hype
Prediction
LowEstimatedHigh
0.000.00006112.21
Details
Intrinsic
Valuation
LowRealHigh
0.000.00009612.21
Details
Bollinger
Band Projection (param)
LowerMiddle BandUpper
0.00010.00010.0001
Details
Please note, it is not enough to conduct a financial or market analysis of a single entity such as Er Therapeutics. Your research has to be compared to or analyzed against Er Therapeutics' peers to derive any actionable benefits. When done correctly, Er Therapeutics' competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy toward taking a position in Er Therapeutics.

Er Therapeutics Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Er Therapeutics and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of PNGM and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Er Therapeutics does not affect the price movement of the other competitor.

High positive correlations

TINO
+ 1.0
VRCV
MURCF
+ 1.0
VRCV
MURCF
+ 1.0
TINO
AGYP
+ 0.25
AGSVF
AGSVF
+ 0.23
PRMO
AGYP
+ 0.02
PRMO
  

High negative correlations

AGYP
- 0.57
DBGF
DBGF
- 0.11
AGSVF
DBGF
- 0.02
PRMO
MURCF
- 0.0
IGNE
TINO
- 0.0
IGNE
MURCF
- 0.0
AGYP

Risk-Adjusted Indicators

There is a big difference between PNGM Stock performing well and Er Therapeutics Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Er Therapeutics' multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.
Mean DeviationJensen AlphaSortino RatioTreynor RatioSemi DeviationExpected ShortfallPotential UpsideValue @RiskMaximum Drawdown
VRCV  0.00  0.00  0.00  0.00  0.00 
 0.00 
 0.00 
 0.00 
 0.00 
SLSDF  0.00  0.00  0.00  0.00  0.00 
 0.00 
 0.00 
 0.00 
 0.00 
PRMO  20.28  5.91  0.17  1.09  15.39 
(66.50)
 44.93 
(25.71)
 249.05 
AGSVF  106.25  56.43  0.00 (0.56) 0.00 
 0.00 
 0.00 
 0.00 
 3,585 
AOVTF  0.00  0.00  0.00  0.00  0.00 
 0.00 
 0.00 
 0.00 
 0.00 
DBGF  0.00  0.00  0.00  0.00  0.00 
 0.00 
 0.00 
 0.00 
 0.00 
AGYP  21.38  5.47  0.11  3.17  17.91 
(93.75)
 100.00 
(50.00)
 150.00 
IGNE  0.00  0.00  0.00  0.00  0.00 
 0.00 
 0.00 
 0.00 
 0.00 
TINO  0.00  0.00  0.00  0.00  0.00 
 0.00 
 0.00 
 0.00 
 0.00 
MURCF  0.00  0.00  0.00  0.00  0.00 
 0.00 
 0.00 
 0.00 
 0.00 

Er Therapeutics Competitive Analysis

The better you understand Er Therapeutics competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Er Therapeutics' competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Er Therapeutics' competition over several years is one of the best ways to analyze its investment potential.
    
 Better Than Average     
    
 Worse Than Peers    View Performance Chart
PNGM VRCV PRMO AGSVF DBGF AGYP TINO MURCF
 0.00 
 0.0001 
PNGM
 0.00 
 0 
Varca
 0.00 
 0.04 
Prom
 26.67 
 0.11 
Argentum
 0.00 
 0.0001 
Panex
 100.00 
 0.0002 
Allied
 0.00 
 0.0002 
Tamino
 0.00 
 0.01 
Lightspeed
Market Volatility
(90 Days Market Risk)
Out of control
Very steady
Out of control
Out of control
Out of control
Out of control
Very steady
Very steady
Market Performance
(90 Days Performance)
Weakest
Weakest
Good
Fair
Fair
Fair
Weakest
Weakest
Odds of Financial Distress
(Probability Of Bankruptcy)
Risky
Risky
Low
Moderate
Low
Moderate
Risky
Hazard
Current Valuation
(Equity Enterprise Value)
Over Valued
Over Valued
Over Valued
Over Valued
Over Valued
Over Valued
Over Valued
Over Valued
Buy or Sell Advice
(Average Analysts Consensus)
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Trade Advice
(90 Days Macroaxis Advice)
Strong Sell
Strong Sell
Sell
Strong Sell
Strong Sell
Cautious Hold
Strong Sell
Not Rated
Current Ratio
0.01 X
0.01 X
78.69 X
16.28 X
3.02 X
N/A
0.33 X
0.49 X
Net Asset
423.6 K
1.37 M
18.33 M
1.03 M
633 K
11.89 K
650 K
28.38 K
Profit Margin
N/A
N/A
0.49 %
N/A
N/A
N/A
(1.10) %
N/A
EBITDA
N/A
(3.21 M)
4.67 M
(212.31 K)
N/A
N/A
(3.01 M)
(193.07 K)
Current Valuation
122.36 K
842.98 K
23.04 M
1.56 M
1.23 M
N/A
7.62 M
209.13 K
Price To Book
143,650 X
N/A
N/A
1.00 X
2.90 X
N/A
2.46 X
22.35 X
Operating Margin
N/A
N/A
0.48 %
N/A
N/A
N/A
(1.08) %
N/A
Current Asset
7 K
11 K
16.52 M
N/A
1000 K
7 K
649 K
N/A
Retained Earnings
N/A
(7.71 M)
(64.03 M)
N/A
(14 M)
(1.56 M)
(19.51 M)
N/A
Beta
12.51
0.52
-0.67
1.67
-1171.57
5.6
0.82
-1.14
Number Of Employees
N/A
9
15
13
3
1
16
7
Shares Outstanding
58.26 M
7.02 M
8.42 B
51.6 M
1.12 B
N/A
N/A
10.5 M
Cash Flow From Operations
(161.43 K)
(1.22 M)
2.57 M
(248.68 K)
(552.78 K)
(218.76 K)
(189.57 K)
(97.48 K)
Annual Yield
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Total Debt
48.49 K
N/A
7.59 M
N/A
N/A
N/A
400 K
24 K
Return On Equity
N/A
N/A
N/A
-0.52
-0.32
N/A
-155.59
N/A
Z Score
N/A
-14.8
-4.2
N/A
-29.6
N/A
-43.8
12.0
Return On Asset
-0.95
N/A
N/A
-0.21
-0.66
N/A
-0.95
-4.97
Book Value Per Share
(0) X
(0.20) X
0 X
0.02 X
N/A
N/A
(0.06) X
(0.04) X
Current Liabilities
645 K
1.5 M
4.18 M
N/A
N/A
736 K
1.26 M
N/A
Total Asset
423.6 K
1.37 M
18.33 M
1.03 M
633 K
11.89 K
650 K
28.38 K
Debt To Equity
N/A
N/A
0.51 %
N/A
0.03 %
N/A
0.63 %
N/A
Shares Owned By Institutions
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Market Capitalization
5.83 K
1.4 M
841.82 K
2.91 M
6
N/A
7.62 M
1.29 M
Price To Earning
(0.06) X
(0.24) X
0.20 X
N/A
N/A
N/A
N/A
N/A
Price To Sales
N/A
N/A
0.19 X
N/A
N/A
N/A
2.14 X
N/A
Net Income
(426.95 K)
(2.4 M)
2.31 M
(375.53 K)
(163.41 K)
(215.95 K)
(389.13 K)
(193.07 K)
Earnings Per Share
N/A
(0.50) X
0 X
(0) X
N/A
N/A
(1.85) X
(0.01) X
Shares Owned By Insiders
N/A
N/A
0.06 %
62.18 %
32.26 %
N/A
N/A
4.76 %
Revenue
N/A
N/A
6.17 M
N/A
N/A
N/A
N/A
N/A
Working Capital
(638 K)
(1.49 M)
12.35 M
N/A
1000 K
N/A
(608 K)
N/A
Cash And Equivalents
650
9.1 K
569.17 K
971.03 K
633 K
N/A
139.12 K
73.56 K
Cash Per Share
N/A
N/A
N/A
0.02 X
N/A
N/A
0.06 X
0.01 X
Gross Profit
N/A
N/A
5.25 M
N/A
(221.6 K)
N/A
1.38 M
N/A
Day Typical Price
1.0E-4
0.001
0.04
0.11
1.0E-4
2.0E-4
2.0E-4
0.01
Daily Balance Of Power
0.0
0.0
0.0
0
0.0
9.2 T
0.0
0.0
Period Momentum Indicator
N/A
N/A
N/A
(0.04)
N/A
1.0E-4
N/A
N/A
Rate Of Daily Change
1.0
1.0
1.0
0.73
1.0
2.0
1.0
1.0
Day Median Price
1.0E-4
0.001
0.04
0.11
1.0E-4
2.0E-4
2.0E-4
0.01
Price Action Indicator
N/A
N/A
N/A
(0.02)
N/A
1.0E-4
N/A
N/A
Relative Strength Index
N/A
N/A
54.03
74.99
100.0
52.69
N/A
N/A
Coefficient Of Variation
846.02
N/A
675.97
839.73
N/A
666.33
N/A
N/A
Mean Deviation
74.65
N/A
20.28
106.25
N/A
21.38
N/A
N/A
Jensen Alpha
38.09
N/A
5.91
56.43
N/A
5.47
N/A
N/A
Total Risk Alpha
17.18
N/A
3.56
24.83
N/A
3.23
N/A
N/A
Sortino Ratio
N/A
N/A
0.1675
N/A
N/A
0.1067
N/A
N/A
Downside Variance
N/A
N/A
1337.84
N/A
N/A
2658.73
N/A
N/A
Standard Deviation
308.14
N/A
41.79
438.38
N/A
37.02
N/A
N/A
Kurtosis
65.8
N/A
12.15
65.91
N/A
2.52
N/A
N/A
Potential Upside
N/A
N/A
44.93
N/A
N/A
100.0
N/A
N/A
Treynor Ratio
(0.99)
N/A
1.09
(0.56)
N/A
3.17
N/A
N/A
Maximum Drawdown
2596.15
N/A
249.05
3585.2
N/A
150.0
N/A
N/A
Variance
94949.12
N/A
1746.55
192176.5
N/A
1370.37
N/A
N/A
Market Risk Adjusted Performance
(0.98)
N/A
1.1
(0.55)
N/A
3.18
N/A
N/A
Risk Adjusted Performance
0.0966
N/A
0.1183
0.0973
N/A
0.1198
N/A
N/A
Skewness
8.11
N/A
3.2
8.12
N/A
1.48
N/A
N/A
Semi Deviation
N/A
N/A
15.39
N/A
N/A
17.91
N/A
N/A
Information Ratio
0.118
N/A
0.1466
0.119
N/A
0.1486
N/A
N/A
Value At Risk
N/A
N/A
(25.71)
N/A
N/A
(50.00)
N/A
N/A
Expected Short fall
N/A
N/A
(66.50)
N/A
N/A
(93.75)
N/A
N/A
Downside Deviation
N/A
N/A
36.58
N/A
N/A
51.56
N/A
N/A
Semi Variance
N/A
N/A
236.95
N/A
N/A
320.86
N/A
N/A

Er Therapeutics Competition Performance Charts

Five steps to successful analysis of Er Therapeutics Competition

Er Therapeutics' competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Er Therapeutics in relation to its competition. Er Therapeutics' competition analysis typically involves several steps, including:
  • Identifying the key players in the market: This involves identifying the major competitors of Er Therapeutics in the market, both direct and indirect, as well as new entrants and disruptive technologies.
  • Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
  • Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Er Therapeutics' competitive landscape.
  • Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Er Therapeutics, and developing a strategy to address them.
  • Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Competitive analysis is an essential tool for businesses to stay ahead of the competition and can be used to inform decision-making and strategy development. By understanding the competitive landscape and staying informed about the activities of competitors, a company can make more informed decisions and improve its overall performance.

Complement your Er Therapeutics position

In addition to having Er Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Wireless Thematic Idea Now

Wireless
Wireless Theme
Companies providing wireless technology and communication services. The Wireless theme has 38 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Wireless Theme or any other thematic opportunities.
View All  Next Launch
When determining whether Er Therapeutics is a strong investment it is important to analyze Er Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Er Therapeutics' future performance. For an informed investment choice regarding PNGM Stock, refer to the following important reports:
How To Invest In PNGM
Details
Is PNGM Stock a good investment?
Details
What is Er Therapeutics' Net Worth?
Details
Largest Other Industrial Metals & Mining Companies
View
Largest Basic Materials Companies
View
Check out Er Therapeutics Correlation with its peers.
To learn how to invest in PNGM Stock, please use our How to Invest in Er Therapeutics guide.
You can also try the Equity Search module to search for actively traded equities including funds and ETFs from over 30 global markets.
Will Diversified Metals & Mining sector continue expanding? Could PNGM diversify its offerings? Factors like these will boost the valuation of Er Therapeutics. Anticipated expansion of PNGM directly elevates investor willingness to pay premium valuations. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Er Therapeutics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Return On Assets
(0.95)
Investors evaluate Er Therapeutics using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Er Therapeutics' intrinsic value—the estimated true worth—helps identify when the stock trades at a discount or premium to fair value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. External factors like market trends, sector rotation, and investor psychology can cause Er Therapeutics' market price to deviate significantly from intrinsic value.
Altman
Z Score
Details
Piotroski
F Score
Details
Beneish
M Score
Details
Financial
Analysis
Details
Buy or Sell
Advice
Details
Technical
Analysis
Details
It's important to distinguish between Er Therapeutics' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Er Therapeutics should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Conversely, Er Therapeutics' market price signifies the transaction level at which participants voluntarily complete trades.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY